Wire · opportunities
On 4th try, Outlook scores FDA nod for reformulated version of Roche's Avastin for AMD
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 July 2026 · Fusion42 review
Outlook Therapeutics secured FDA approval for Lytenava, a purpose-built ophthalmic formulation of bevacizumab for wet AMD, after three rejections and a successful formal dispute resolution appeal. The drug enters an $8.5 billion U.S. market dominated by Regeneron's Eylea and Roche's Vabysmo, with 12 years of reference product exclusivity under BPCIA.
This Wire brief sits within Fusion42's coverage of Medtech.
◆ ◆ The Wire takeaway
A low-cost, FDA-approved formulation of a 20-year-old drug has just become legal in the US ophthalmology market. If you supply manufacturing, cold chain, or patient access infrastructure to eye clinics, you now have a proven entrant competitor whose unit economics force the incumbents to cut price or service.
◆ Coverage
1 source · 27 Jul 2026
◆ Related on Wire
◆ Topics